Format

Send to

Choose Destination
Am J Cardiol. 1996 Nov 7;78(9A):7-12.

Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist.

Author information

1
State University of New York at Buffalo, USA.

Abstract

Calcium antagonists are a heterogeneous group of drugs, each with a different chemical structure and cardiovascular profile. Distinguishing factors include pharmacokinetics, mode of calcium mobilization affected, class and subclass of calcium channel inhibited, state-dependent interactions, and effect of disease on the drug's activity. A new calcium antagonist, mibefradil, has a unique chemical structure and cardiovascular profile compared with those currently available, and it appears to represent a new class of calcium antagonists.

PMID:
8903279
DOI:
10.1016/s0002-9149(96)00732-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center